Skip to content

Exploring the Optimal Timing for Discontinuation of Fospropofol Disodium for Maintenance of General Anesthesia: A Prospective, Multicenter, Randomized, Controlled Study

The Optimal Management Protocol for Fospropofol Disodium Combined with Esketamine in General Anesthesia: A Prospective, Multicenter, Randomized, Controlled Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111911
Enrollment
Unknown
Registered
2025-11-07
Start date
2025-11-17
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chest diseases

Interventions

Group 0:Immediate discontinuation at the end of surgery
Group T1:Discontinuation 10 minutes before the end of surgery
Group T2:Discontinuation 15 minutes before the end of surgery
Group T3:Discontinuation 20 minutes before the end of surgery

Sponsors

Tai'an Central Hospital (Qingdao University Affiliated Tai'an Central Hospital, Taishan Medical Care Center)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. American Society of Anesthesiologists (ASA) physical status class I–III; 2. Aged 18–65 years, Gender inclusive; 3.Scheduled for elective thoracoscopic lobectomy or segmentectomy under general anesthesia with an expected operative time > 2 h; 4.Body-mass index (BMI) 18.0–30.0 kg/m^2; 5.Voluntary signing of the informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of severe cardiac, cerebral, hepatic, renal, or pulmonary disease; 2.Obesity (BMI > 30.0 kg/m^2) or underweight (BMI < 18.0 kg/m^2); 3.Expected post-operative admission to the Intensive Care Unit (ICU) or return to ward with an endotracheal tube in situ; 4.Surgery within the preceding 2 months or participation in any other clinical drug trial within the past 2 months; 5. Severe disturbance of consciousness, cognitive dysfunction, or central nervous system disorders (e.g., psychiatric illness, Parkinson’s disease, Alzheimer’s disease); 6. Known or suspected hypersensitivity or contraindication to any component of the study drugs or protocol-specified medications (sufentanil citrate injection, remifentanil hydrochloride for injection, fospropofol disodium for injection, etc.).

Design outcomes

Primary

MeasureTime frame
Time from the end of surgery to patient emergence;

Secondary

MeasureTime frame
Cumulative dose of fospropofol disodium;Emergence quality score;Emergence agitation;Extubation time;PACU length of stay;Hemodynamic parameters at different time points;

Countries

China

Contacts

Public ContactZaiqi Yang

Tai'an Central Hospital (Qingdao University Affiliated Tai'an Central Hospital, Taishan Medical Care Center)

yang_zaiqi@126.com+86 133 7538 8816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026